Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, and Maryland Department of Health and Mental Hygiene.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation.
Authors Conflict of Interest Disclosure: Jennifer Bradley disclosed that she is employed by Janssen-Cilag, which markets Eprex®. Belinda Butcher disclosed that she provided statistical and medical writing services funded by Janssen-Cilag. All other authors reported no actual or potential conflict of interest in relation to this continuing nursing education activity.
Nephrology Nursing Journal Editorial Board Statements of Disclosure: Deborah H. Brooks, MSN, APN-BC, CNNNP, disclosed that she is on the Consultant Presenter Bureau and the Advisory Board for Affymax, Inc.
Paula Dutka, MSN, RN, CNN, disclosed that she has received grant/research support from Keryx, Amgen, Rockwell, Fibrogen, Dynovox, and Otsuka; and she is on the Consultant and Presenter Bureau and the Nephrology Nurse Advisory Board for Affymax/Takeda.
Patricia B. McCarley, MSN, RN, ACNPc, CNN, disclosed that she is on the Consultant Presenter Bureau for Amgen, Genzyme, and OrthoBiotech. She is also on the Advisory Board for Amgen, Genzyme, and Roche and is the recipient of unrestricted educational grants from OrthoBiotech and Roche.
All other members of the Editorial Board had no actual or potential conflict of interest in relation to this continuing nursing education activity.
This article was reviewed and formatted for contact hour credit by Beth Ulrich, EdD, RN, FACHE, FAAN, Nephrology Nursing Journal Editor, and Hazel A. Dennison, DNP, RN, APNc, CPHQ, CNE, ANNA Education Director.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Non-Endorsement of Products: Accreditation of activities for contact hours does not imply approval or endorsement of any product, advertising, or educational content by the American Nephrology Nurses' Association (ANNA), or the American Nurses Credentialing Center’s Commission on Accreditation.
Accreditation Statement: American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Accreditation status does not imply endorsement by ANNA or ANCC of any commercial product.
ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.
Goal: To provide an overview of the effects of changing the frequency of the administration of erythropoietin-stimulating agent on hemoglobin levels in patients on peritoneal dialysis.
Explain the impact of less frequent medication administration of erythropoietin-stimulating agents (ESAs) for patients on peritoneal dialysis on hemoglobin variability.
Discuss the key findings of this study on patients who are on peritoneal dialysis.
Review the limitations and implications for further research on patients who are on peritoneal dialysis related to the findings of this study.
You must be logged in and own this product in order to